Wire flash
139 Institutions Join China Reform Health Management's Earnings Call, with China Southern Fund Sending 20 Participants
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Guoxin Health (000503) held a performance briefing via conference call on September 22, attracting 139 institutional investors including major fund companies like E Fund, China Asset Management, and Southern Fund, with the latter sending 20 participants. Despite high institutional interest, active equity fund holdings were limited as of June, with mainly index funds holding positions. The company reported that its health services revenue grew rapidly in the first half of 2023, driven by chronic disease management and health management business expansion. Guoxin Health is integrating AI technology with health service scenarios to improve efficiency and user experience, particularly in Shandong Province. The company noted significant seasonal revenue patterns, with an average of 52.6% of annual revenue coming in the fourth quarter over the past five years. Management outlined plans to stabilize traditional business while developing innovative high-margin business segments as a second growth curve. For the first half of 2023, revenue was 102 million yuan (up 6.3% year-on-year) with a net loss of 102 million yuan (narrowing 3.21%). The stock has fallen 23.87% year-to-date, with a market capitalization of 6.62 billion yuan.
Source report
Despite a shortened trading week due to the Mid-Autumn Festival (September 21–25), institutional research activity remained robust. According to Wind Information, 427 A-share listed companies were surveyed by institutions this week.
Sinocare Health (000503) attracted the highest number of institutional investors, with 139 firms participating—the only company to exceed 100. Other notable names include Sinomach Precision Industry (002046) and Star Lake Bioscience (300464), each drawing over 40 institutions, while SF Diamond (300179) and Espressif Systems (688018) each saw more than 30.
Earnings Call Details
Sinocare Health held its earnings conference call on September 22 in a teleconference format. The 139 participating institutions included public funds, private equity firms, securities companies, insurance companies, and bank wealth management units. Notable participants included:
- E Fund Management
- China Asset Management
- Southern Fund
- Raymond James (Ruijing) Fund
- Gaoyi Asset Management
- Juming Investment
Several institutions sent multiple representatives. Southern Fund notably dispatched 20 participants. A number of high-profile fund managers also attended, including:
- Yang Zongchang (E Fund)
- Gao Xiang and Zhu Yi (China Asset Management)
- Sun Lumin and Zhang Yanmin (Southern Fund)
- Shen Aiqian (Ping An Fund)
- Qiu Jie (Qianhai Open Source Fund)
Fund Holdings Snapshot
Despite the high level of institutional interest, data from end-June shows that few actively managed equity funds held Sinocare Health shares. Most holdings were concentrated in index funds.
Health Services Business Growth
Regarding the company's fast-growing health services segment, Sinocare Health attributed the strong first-half revenue growth to the continued rollout of chronic disease management and health management services. The company noted it is leveraging its long-term expertise in the medical, pharmaceutical, and insurance sectors to:
- Enhance chronic disease management service systems
- Strengthen supply chain assurance, platform support, and intelligent service capabilities
- Integrate AI technology with health service scenarios to improve efficiency and user experience
In Shandong Province, the company's chronic disease management business continues to advance, with a focus on refined operations and service capability improvement.
Future Strategy
Sinocare Health stated it will pursue steady operations and promote the integration of AI and other new technologies with health services. The company aims to explore a "platform + data"-driven health service model to cultivate new growth drivers for long-term development.
Revenue Seasonality and Profitability Outlook
Addressing the seasonal nature of its revenue and the path to narrowing non-recurring losses, Sinocare Health noted that historically, revenue is heavily concentrated in the fourth quarter. Over the past five years, Q4 revenue has accounted for an average of 52.6% of full-year revenue.
The company outlined two key priorities moving forward:
- Strengthen the traditional business base to improve both revenue scale and quality.
- Accelerate the rollout of innovative businesses to cultivate high-margin growth points.
By improving efficiency in traditional operations and driving volume growth in new businesses, Sinocare Health aims to create a "second growth curve", steadily improve recurring net profit, and enhance overall profitability.
Financial Performance and Market Data
In the first half of 2026, Sinocare Health reported:
- Revenue: RMB 102 million, up 6.3% year-on-year
- Net loss attributable to shareholders: RMB 102 million, narrowing 3.21% year-on-year
The company's share price has fallen 23.87% year-to-date, with a current total market capitalization of RMB 6.62 billion.
Source
同花顺财经Neutral / independent